Caplacizumab治疗免疫性血栓性血小板减少性紫癜的研究进展

田竑; 殷杰; 余自强

doi:10.13201/j.issn.1004-2806.2023.11.015

Caplacizumab治疗免疫性血栓性血小板减少性紫癜的研究进展

- 1.
  国家血液系统疾病临床医学研究中心(江苏苏州，215006)
- 2.
  江苏省血液研究所
- 3.
  苏州大学附属第一医院血液科
- 4.
  国家卫生健康委员会血栓与止血重点实验室

详细信息

通讯作者: 余自强，E-mail：yuziqiang@suda.edu.cn

^Δ审校者

中图分类号: R558

收稿日期: 2022-11-09

刊出日期: 2023-11-01

Research update on Caplacizumab in the treatment of immune thrombotic thrombocytopenic purpura

- 1.
  National Clinical Research Center or Hematologic Diseases, Suzhou, 215006, China
- 2.
  Jiangsu Institute of Hematology
- 3.
  Department of Hematology, The First Affiliated Hospital of Soochow University
- 4.
  NHC Key Laboratory of Thrombosis and Hemostasis

More Information

Corresponding author: YU Ziqiang, E-mail: yuziqiang@suda.edu.cn

Received Date: 09 November 2022

Publish Date: 01 November 2023

摘要

摘要: 免疫性血栓性血小板减少性紫癜(immune thrombotic thrombocytopenic purpura，iTTP)是一种危及生命的免疫介导的血栓性微血管病，其特征为重度血小板减少、溶血性贫血和组织器官缺血。治疗性血浆置换联合糖皮质激素虽是目前iTTP的主要治疗手段，但部分患者治疗无效或复发。Caplacizumab是一种新型纳米抗体，可与血管性血友病因子(vWF)的A1结构域结合，并特异性抑制vWF和血小板GPIb区之间的相互作用，从而减少vWF介导的微血栓形成。近年来，多项研究探索了其临床应用价值。该综述将详述Caplacizumab治疗iTTP的最新进展和治疗建议。
- 血栓性血小板减少性紫癜 /
- 纳米抗体 /
- Caplacizumab
Abstract: Immune thrombotic thrombocytopenic purpura(iTTP) is a life-threatening immune-mediated thrombotic microvascular disease characterized by severe thrombocytopenia, hemolytic anemia and organ ischemia. Although therapeutic plasma exchange combined with corticosteroids is the main treatment for iTTP at present, some patients still suffer from treatment failure and/or relapse. It is urgent to solve this unmet medical need. Caplacizumab is a novel nanoantibody that binds to the A1 domain of von Willebrand factor(vWF) and specifically inhibits the interaction between vWF and the GPIb domain of platelets, thereby reducing vWF-mediated microthrombosis. In recent years, many studies have explored its clinical value. This review will summarize the latest progress and treatment recommendations of Caplacizumab in the treatment of iTTP.
- thrombotic thrombocytopenic purpura /
- nanobody /
- Caplacizumab

HTML全文

参考文献(26)

[1]	Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features[J]. Br J Haematol, 2008, 142(5): 819-826. doi: 10.1111/j.1365-2141.2008.07276.x
[2]	Pollissard L, Shah A, Punekar RS, et al. Burden of illness among Medicare and non-Medicare US populations with acquired thrombotic thrombocytopenic purpura[J]. J Med Econ, 2021, 24(1): 706-716. doi: 10.1080/13696998.2021.1922262
[3]	Reese JA, Muthurajah DS, Kremer Hovinga JA, et al. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features[J]. Pediatr Blood Cancer, 2013, 60(10): 1676-1682. doi: 10.1002/pbc.24612
[4]	Elverdi T, Eskazan AE. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura[J]. Drug Des Devel Ther, 2019, 13: 1251-1258. doi: 10.2147/DDDT.S134470
[5]	王文, 何杨. 血栓性血小板减少性紫癜治疗的研究进展[J]. 中国实验血液学杂志, 2022, 30(1): 314-318. doi: 10.19746/j.cnki.issn1009-2137.2022.01.052
[6]	中华医学会血液学分会血栓与止血学组. 血栓性血小板减少性紫癜诊断与治疗中国指南(2022年版)[J]. 中华血液学杂志, 2022, 43(1): 7-12.
[7]	韩悦, 戚嘉乾. 血栓性血小板减少性紫癜诊治进展[J]. 临床血液学杂志, 2021, 34(1): 5-8. doi: 10.13201/j.issn.1004-2806.2021.01.002
[8]	李蓉蓉, 白秋江. 首个治疗成年获得性血栓性血小板减少性紫癜的纳米抗体药物caplacizumab[J]. 中国药师, 2020, 23(3): 520-523. doi: 10.3969/j.issn.1008-049X.2020.03.029
[9]	Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura[J]. J Thromb Haemost, 2020, 18(10): 2496-2502. doi: 10.1111/jth.15010
[10]	Ulrichts H, Silence K, Schoolmeester A, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs[J]. Blood, 2011, 118(3): 757-765. doi: 10.1182/blood-2010-11-317859
[11]	van Bockstaele F, Holz JB, Revets H. The development of nanobodies for therapeutic applications[J]. Curr Opin Investig Drugs, 2009, 10(11): 1212-1224.
[12]	Li BX, Qin XH, Mi LZ. Nanobodies: from structure to applications in non-injectable and bispecific biotherapeutic development[J]. Nanoscale, 2022, 14(19): 7110-7122. doi: 10.1039/D2NR00306F
[13]	陈霞, 赵建中, 王松. 首个纳米抗体药Caplacizumab的研发历程[J]. 中国临床药理学杂志, 2021, 37(18): 2535-2539. doi: 10.13699/j.cnki.1001-6821.2021.18.038
[14]	原博, 王杰文, 康广博, 等. 双特异性纳米抗体的研究进展及其应用[J]. 中国生物工程杂志, 2021, 41(2): 78-88. doi: 10.13523/j.cb.2011027
[15]	孙山, 谭星, 庞晓燕, 等. 纳米抗体技术应用的最新进展[J]. 生物工程学报, 2022, 38(3): 855-867. doi: 10.13345/j.cjb.210464
[16]	Ablynx NV. CABLIVI(caplacizumab-yhdp)FDA Label[EB/OL]. (2022-02-23)[2022-04-01]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761112s009lbl.pdf.
[17]	Sargentini-Maier ML, de Decker P, Tersteeg C, et al. Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura[J]. Expert Rev Clin Pharmacol, 2019, 12(6): 537-545. doi: 10.1080/17512433.2019.1607293
[18]	Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic Purpura[J]. N Engl J Med, 2016, 374(6): 511-522. doi: 10.1056/NEJMoa1505533
[19]	Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic Purpura[J]. N Engl J Med, 2019, 380(4): 335-346. doi: 10.1056/NEJMoa1806311
[20]	Scully M, de la Rubia J, Pavenski K, et al. Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura(aTTP): The Post-HERCULES Study[J]. Blood, 2021, 138: 2080. doi: 10.1182/blood-2021-148839
[21]	Coppo P, Bubenheim M, Azoulay E, et al. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP[J]. Blood, 2021, 137(6): 733-742. doi: 10.1182/blood.2020008021
[22]	Dutt T, Shaw RJ, Stubbs M, et al. Real-world experience with caplacizumab in the management of acute TTP[J]. Blood, 2021, 137(13): 1731-1740. doi: 10.1182/blood.2020007599
[23]	Kühne L, Kaufeld J, Völker LA, et al. Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura[J]. J Thromb Haemost, 2022, 20(4): 951-960. doi: 10.1111/jth.15637
[24]	Völker LA, Kaufeld J, Miesbach W, et al. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura[J]. Blood Adv, 2020, 4(13): 3085-3092. doi: 10.1182/bloodadvances.2020001973
[25]	Völker LA, Brinkkoetter PT, Knöbl PN, et al. Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab[J]. J Thromb Haemost, 2020, 18(11): 3061-3066. doi: 10.1111/jth.15045
[26]	Sriya G, Angela H, Menapace Laurel A, et al. A phase 3 study to evaluate the efficacy and safety of caplacizumab without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombocytopenic Purpura[J]. Blood, 2022, 140(S1): 2770-2771.